New drug KINE-101 tested for tough nerve disorder
NCT ID NCT07343310
First seen Jan 19, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-stage study tested a single dose of a new drug called KINE-101 in 9 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that did not improve with steroids. The main goal was to check safety and side effects over 28 days. Researchers also looked at whether the drug might help with nerve function and immune system changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk Samsung Hospital
Seoul, Seoul, 03181, South Korea
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.